Genovese_Kremer_Mar2017

More documents

Recommendations

Info

Results – Safety Data Through Week 12 (Study 2) Adverse events, n (%) Placebo n=56 3 mg BID n=55 6 mg BID n=55 ABT-494 12 mg BID n=55 18 mg BID n=55 Any AE 25 (45) 26 (47) 31 (56) 37 (67) 39 (71) Any SAE 1 (2) 2 (4) 2 (4) 0 1 (2) Any AE leading to discontinuation 2 (4) 0 6 (11) 2 (4) 2 (4) AEs of special interest* Infection 12 (23) 11 (20) 12 (22) 22 (40) 21 (38) Serious infections 1 (2) 0 0 0 0 Cardiovascular event 0 0 1 (2)† 0 0 Herpes zoster 2 (4) 1 (2) 0 1 (2) 1 (2) Hepatic disorder 1 (2) 0 0 0 2 (4) Malignancy 0 0 1 (2)‡ 0 0 *Reported by the investigator; †Adjudicated as a transient ischemic attack by an externally led cardiovascular adjudication committee; ‡Basal cell and squamous carcinoma. Kremer JM, et al. Arthritis Rheum 2016;68:2867–77.
Conclusions • Selective JAK-1 inhibition with ABT-494 was effective in: – Patients with active RA and an inadequate response to MTX who were receiving background MTX – Refractory patients with an inadequate response to or intolerance of 1 anti- TNF agent • ABT-494 demonstrated a safety and tolerability profile consistent with other JAK inhibitors in RA – With high dosages (12/18 mg BID), the rate of infections was increased (40% in the 12 mg BID group 2 ) • Larger Phase 3 trials are underway to confirm the selectivity of ABT-494 against JAK- 1 and to determine whether this translates to an improved benefit–risk profile across a wide spectrum of patients with RA 1. Genovese MC, et al. Arthritis Rheum 2016;68:2857–66. 2. Kremer JM, et al. Arthritis Rheum 2016;68:2867–77.
Page 1 and 2: Phase 2b Studies of ABT-494, a Sele
Page 3 and 4: Background and Objectives • ABT-4
Page 5 and 6: Methods - Study Design • These we
Page 7 and 8: Results - Baseline Demographics and
Page 9 and 10: Results - Primary Endpoint MTX inad
Page 11 and 12: Response rate (%) Response rate (%)
Page 13: Results - Safety Data Through Week

Genovese_Kremer_Mar2017

Create successful ePaper yourself

Delete template?

Save as template?